Search Results

Virpax ® Pharmaceuticals, Inc. today announced that it has entered into a term sheet to settle the litigation with the Company and Sorrento Therapeutics, Inc. (Sorrento) and Scilex Pharmaceuticals, Inc. (Scilex and Sorento, collectively, the “Plaintiffs”).

Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento” or “Company”) announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company (Nasdaq: SCLX, “Scilex”) of certain securities that Sorrento held in Scilex.

Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) announced today positive Phase 2a top-line clinical trial results for the RTX program.

Scilex Holding Company announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc..

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. and Sorrento executed non-binding term sheets relating to, among other things, the Securities Transfer and the Note.

Sorrento Therapeutics, Inc. announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order approving an offering of a portion of Sorrento’s common stock in its non-debtor public subsidiary, Scilex Holding Company.

Sorrento Therapeutics, Inc. announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order extending the expiration of the restrictions on transfer on the shares of common stock of Scilex Holding Company that were distributed by Sorrento to its stockholders as a dividend on January 19, 2023.

Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) announced today positive topline results of a pivotal Phase 3 study of Sorrento’s oral Mpro inhibitor, Ovydso (Olgotrelvir, STI-1558), in mild or moderate symptomatic adults infected with SARS-CoV-2, or COVID-19, irrespective of risk factors for severe complications.

Sorrento Therapeutics, Inc. announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order approving a $105 million “stalking horse” bid for substantially all of the Debtors’ common stock, preferred stock, and warrants in Scilex Holding Company to Oramed Pharmaceuticals, Inc..

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements:.